Observational multicenter study to evaluate the prevalence and prognosis of subclinical atheromatosis in a Spanish chronic kidney disease cohort: baseline data from the NEFRONA study

Chronic kidney disease (CKD) is a growing health problem, with increasing morbidity, mortality and monetary costs [1]. Despite the improvement in the treatment of its complications, patients with CKD in any stage continue to have a higher rate of cardiovascular events than subjects with normal renal function. In fact, cardiovascular disease (CVD) continues to be the first mortality cause in this population, and in many recent guidelines it has been stated as a cardiovascular risk factor itself, as severe as diabetes [2].

Important advances have been made in the knowledge of both general and specific cardiovascular risk factors in CKD. However, neither traditional risk factors or risk score charts for general population nor emerging risk biomarkers appear to be good enough predictors in this population [3–6]. It has been suggested that there is a different pathogenesis for CVD in advanced CKD, since most cardiovascular deaths appear to be from sudden deaths. These events have been related to possible arrhythmias or heart failure, related to heart remodelling and microischemia of the myocardium [7–9]. Besides, the effects of reverse epidemiology of many traditional risk factors and the appearance of different mechanisms are involved [10–12].

The presence of accelerated atheromatosis in CKD could also play a role in the higher cardiovascular mortality, in a process that has been termed accelerated vascular aging. However, there is still much to clarify regarding the process of atheromatosis in this group of patients, and the precise contribution of various risk factors. Many serum biomarkers are altered in CKD patients, and their prognostic value is currently under study [13, 14], but new tools for adequately assessing asymptomatic atheromatosis are required [15]. The application of diagnostic tests in CKD (i.e. vascular ultrasound or ankle-brachial index) to detect subclinical atheromatosis and adequately stratify cardiovascular risk has not yet been specifically addressed, although there are some initial promising data [16, 17].

The NEFRONA project is an observational multicenter prospective study designed to evaluate the prevalence and evolution of subclinical atheromatosis in CKD patients, as well as the contribution of vascular imaging for a more precise cardiovascular risk assessment [18, 19]. Baseline data of this study are presented in this article.

Results of tests to detect subclinical atheromatosis are showed in Table 4. There was no difference between controls and CKD patients, but cIMT was lower in patients with more advanced CKD (Figure 1). Statistically significant differences were shown when a model was used in which plaques in common carotid arteries were truncated to a cIMT value of 1.5 mm.On the contrary, CKD patients presented a higher prevalence of atheromatous plaques, both globally and in carotid and femoral arteries. No differences were found between CKD stages. It is important to highlight a high rate of patients with femoral but not carotid plaques (Figure 2). Similar results were found with the measure of ABI: higher prevalence of pathologic values in CKD, with a progressive rise of prevalence in more advanced CKD. Besides, as CKD progresses, there are more patients with an ABI compatible with vascular stiffness (ABI >1.4) and lower with an ABI <0.9, compatible with distal ischemia (Figure 3).

	Controls	CKD	CKD stage 3	CKD stages 4-5	CKD stage 5D	p value	p value
	n =559	n =2445	n =937	n =820	n =688	CKD vs controls	Between CKD groups
cIMT (mm)
All patientsa	0.705 (0.605-0.815)	0.725 (0.615-0.870)	0.765 (0.645-0.891)	0.705 (0.600-0.855)	0.695 (0.595-0.850)	<0.001	<0.001
Plaque-free common carotidb	0.710 ± 0.150	0.710 ± 0.160	0.749 ± 0.164	0.699 ± 0.157	0.689 ± 0.154	NS	<0.001
Atheroma plaque presence (%)
Any territory	52.4	70.0	70.5	69.6	70.0	<0.001	NS
Only carotid artery	18.1	18.8	19.3	17.6	19.4	<0.001	NS
Only femoral artery	10.0	12.6	12.9	13.3	11.2	<0.001	NS
Carotid and femoral arteries	24.3	38.7	38.3	38.6	39.3	<0.001	NS
ABI
Mean ABI	1.03 ± 0.10	1.06 ± 0.27	1.02 ± 0.19	1.05 ± 0.21	1.14 ± 0.38	NS	<0.001
Pathologic ABI (%)	12.3	28.0	25.3	27.1	32.9	<0.001	0.003
ABI >1.4 (%)	1.4	11.0	5.6	10.2	19.5	<0.001	<0.001
ABI <0.9 (%)	10.9	17.0	19.8	16.9	13.4	<0.001	0.003
Atheromatosis score (%)						<0.001	NS
AS 0	38.1	30.3	28.4	33.4	29.3
AS 1	20.0	11.5	13.1	9.9	11.0
AS 2	41.7	53.5	54.1	51.5	55.2
AS 3	0.0	4.4	4.2	5.0	4.1

Data expressed as percentage or mean value ± standard deviation. ^aValues for all the patients, truncating IMT values of patients with plaques at 1.5 mm. Data expressed as median (interquartile interval). ^bValues for patients with no plaque in any common carotid artery. Abbreviations: CKD chronic kidney disease, cIMT common carotid intima-media thickness, ABI ankle-brachial index, AS atheromatosis score, NS not significant.

Finally, AS was evaluated, with a higher rate of worse scores in CKD patients, but no significant differences between stages.

NEFRONA is the first large cohort study evaluating the prevalence and evolution of subclinical atheromatosis in CKD patients, aimed to define the role of non-invasive early diagnostic tests.

Cardiovascular disease is the main cause of morbidity and mortality in CKD patients, and it continues to be so despite the better knowledge on vascular disease pathogenesis and the improvement in CKD treatments [1, 21, 26]. Appropriate evaluation of cardiovascular risk is essential, and several non-invasive and easily performable methods, like vascular ultrasound, are currently under study.

In this population, we found that the CKD-group has a higher age and proportion of male subjects, and higher rates of hypertension, diabetes and dyslipidemia than the controls. However, this worse cardiovascular profile is more pronounced in earlier stages of CKD. The percentage of diabetic and vascular etiologies of CKD is proportionally lower in more advanced stages. Blood pressure values and BMI equally show this trend. These facts could be explained by an incidence-prevalence bias (or Neyman bias), since as renal dysfunction progresses, patients with worse cardiovascular health have a lower possibility of staying free of cardiovascular events, and hence, of being recruited for this study. There is probably a selection bias too, given that patients in CKD stage 5d were significantly younger, and age has been shown the most important risk factor for atheromatosis development. It is also rather remarkable the high rate of well-known cardiovascular risk factors in stage 3 CKD patients. Altogether, it seems increasingly important and evidence-based that primary prevention strategies must be started earlier in the course of the disease.

All evaluated pharmacological treatments are much more frequently prescribed in CKD patients than in controls, as it was expected. Antihypertensive, antidiabetic and hypolipidemic drugs are more common in CKD stages 4-5 than in stage 3, but in dialysis these treatments are much less frequent. This tendency is explained by the baseline differences, but also by the well-known reverse epidemiology effect in cardiovascular risk factors: dialysis patients usually have lower LDL-cholesterol levels, so they are prescribed less statins.

On the other side, treatments for control of anemia and mineral-bone disorders grow exponentially in more advanced CKD stages. Two interesting pieces of information can be highlighted: first, a very low percentage of patients treated with native vitamin D regardless of the stage, despite the usually low plasma levels and the growing evidence of the benefits of vitamin D supplementation [27–30]; second, the high rate of patients in more advanced stages of CKD receiving calcium-based phosphate binders, despite their extremely high risk of vascular calcification.

In the evaluation of laboratory information, mean values show that patients are globally well controlled, and we confirm the reverse epidemiology phenomenon in lipids (the frequently described tendency to spontaneously normalize their lipid profile in end-stage renal disease, that has been associated to more inflammation and malnutrition). It is important to highlight the low values of inflammation markers in all CKD stages. Anemia and mineral-bone disorder parameter analysis appear to show a mainly good adherence to current guidelines, at least in this subpopulation free of cardiovascular history.

cIMT is a good cardiovascular risk marker in subjects with normal renal function [31, 32]. A few studies have also proved that cIMT can predict ischemic events in CKD patients, but most of them were conducted in dialysis patients with small sample sizes [33–37]. In the NEFRONA study, we did not find any difference in cIMT between CKD patients and controls, unless plaque presence was corrected to a higher cIMT value. However, we did find that cIMT was higher in CKD stage 3, and progressively lower with more advanced stages. Again, there seems to be a survival bias involved, given the cross-sectional nature of this data, and an incidence-prevalence bias, since only patients free of prior cardiovascular events were included. It is likely that patients with more advanced CKD have a lower cIMT because those who would have had a higher cIMT probably already had a cardiovascular event. It is a well-known factor that CKD patients have a higher chance of suffering a fatal or non-fatal vascular event than eventually requiring dialysis, so those patients arriving to more advance CKD stages are usually considered “cardiovascular survivors” [21]. This fact should be proved in the prospective analysis of the NEFRONA study. More specific data about cIMT, such as different site measures or differences between left and right cIMT, is under current analysis.

Atheromatous plaque presence directly affects cardiovascular prognosis in general population [38], and it seems clearly involved in CKD morbimortality [39]. There is evidence showing the predictive effect of the presence and extent of vascular plaques on dialysis patients [40, 41]. Besides, the place where calcium is deposited is also important: it seems that intimal rather than medial calcification has a worse prognosis [42–44]. In our study, plaque prevalence is significantly higher in CKD patients than in subjects with normal renal function, but there is no difference between CKD stages. We explain this fact by the same biases as for cIMT; age seems to be the main determinant for the atheromatous load, so only younger patients with less risk factors reach stage 5 CKD free of cardiovascular events.

One interesting finding is the high rate of femoral plaques, even in patients with no carotid atheromatosis (between 10 and 12%). Some studies have started to explore the evaluation of ultrasound diagnosis of femoral plaques in general population and in other pathologies [45, 46]. In CKD, evaluation of this site has been studied by simple radiology, and it has been associated to peripheral artery disease and cardiovascular prognosis [47]. In order to perform an adequate vascular risk assessment, femoral ultrasound should complement carotid ultrasound. More extensive data on the specific characteristics of atheromatous plaques and difference between subgroups is beyond the aim of this article, and it has partially been published [48].

Peripheral artery disease, defined as a pathologic ankle-brachial index has also shown to have a predictive value over new-onset cardiovascular events in non-CKD [49, 50] and CKD subjects [51–53], but again, most data come from dialysis cohorts. In the NEFRONA study, CKD was associated with a pathologic ABI. In more advanced stages of CKD, pathologic ABI was more frequently in the higher rank (>1.4, related to severe vascular calcification) than in the ischemic range (<0.9).

Altogether, CKD patients present a higher atheromatous score than non-CKD subjects, but no difference could be found between CKD stages, probably due to the cross-sectional nature of this initial analysis and the uneven distribution of cardiovascular risk factors. Further and more complete information will be revealed when follow-up data are published.

This study has some limitations, being the first one the cross-sectional nature of these initial results. There is an intentional bias, because only patients with no history of cardiovascular events were included. This bias was necessary, but its consequences have to be considered when interpreting the results. Finally, control subjects are not perfectly matched, and also present a selection bias: they were selected from patients seeking medical attention in Primary Care centers, so they might not be a fully representative sample of the general population.

NEFRONA is the first study presenting the real prevalence of subclinical atheromatosis in a large cohort of CKD patients, compared to subjects with normal renal function. As an added value, all diagnostic tests were performed by the same exploration teams, avoiding differences between observers.

The cardiovascular risk profiles and treatment policies through different CKD stages is also presented. Our results indirectly suggest that patients with more advanced renal dysfunction are those who have avoided cardiovascular events.

Subclinical atheromatosis is very prevalent in chronic kidney disease patients. Femoral atheromatous plaques are very frequent, even in patients without carotid plaques; hence, femoral ultrasound should also be performed for a correct evaluation of cardiovascular risk. Further data on the evolution and prognosis of subclinical atheromatosis will contribute to the understanding of atheromatous disease in kidney disease when the prospective analysis of the NEFRONA study is published. This initial analysis should generate new hypothesis and stimulate the study of the effect of earlier primary prevention strategies on cardiovascular morbidity in CKD patients.

Jose Manuel Valdivielso and Elvira Fernández share senior authorship.